ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
Authors
Keywords
-
Journal
GENES & DEVELOPMENT
Volume 31, Issue 3, Pages 318-332
Publisher
Cold Spring Harbor Laboratory
Online
2017-02-28
DOI
10.1101/gad.290957.116
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Coupling of Homologous Recombination and the Checkpoint by ATR
- (2017) Rémi Buisson et al. MOLECULAR CELL
- The BRCA1- 11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
- (2016) Y. Wang et al. CANCER RESEARCH
- Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA -Mutant Ovarian Cancer Models
- (2016) Hyoung Kim et al. CLINICAL CANCER RESEARCH
- ATM/ATR‐mediated phosphorylation of PALB2 promotes RAD51 function
- (2016) Johanna K Ahlskog et al. EMBO REPORTS
- DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer
- (2016) Daniela Kurfurstova et al. Molecular Oncology
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1 -Mutant Ovarian Cancer
- (2016) Young Eun Choi et al. Cell Reports
- Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
- (2015) Christopher J. Lord et al. Annual Review of Medicine
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- Resistance to therapy inBRCA2mutant cells due to loss of the nucleosome remodeling factor CHD4
- (2015) Shawna Guillemette et al. GENES & DEVELOPMENT
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the DNA Damage Response in Cancer
- (2015) Mark J. O’Connor MOLECULAR CELL
- MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5′ end resection
- (2015) Vera Boersma et al. NATURE
- A mechanism for the suppression of homologous recombination in G1 cells
- (2015) Alexandre Orthwein et al. NATURE
- REV7 counteracts DNA double-strand break resection and affects PARP inhibition
- (2015) Guotai Xu et al. NATURE
- Mammalian RAD51 paralogs protect nascent DNA at stalled forks and mediate replication restart
- (2015) Kumar Somyajit et al. NUCLEIC ACIDS RESEARCH
- Homologous Recombination and Human Health: The Roles of BRCA1, BRCA2, and Associated Proteins
- (2015) Rohit Prakash et al. Cold Spring Harbor Perspectives in Biology
- Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model
- (2015) Bhagwan Yadav et al. Computational and Structural Biotechnology Journal
- A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments
- (2015) Kareem N. Mohni et al. PLoS One
- Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer
- (2014) Shaohua Chen et al. CANCER LETTERS
- PTIP associates with Artemis to dictate DNA repair pathway choice
- (2014) Jiadong Wang et al. GENES & DEVELOPMENT
- Phosphorylated RPA recruits PALB2 to stalled DNA replication forks to facilitate fork recovery
- (2014) Anar K. Murphy et al. JOURNAL OF CELL BIOLOGY
- Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility
- (2014) M. Yu et al. SCIENCE
- ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status
- (2013) C. J. Huntoon et al. CANCER RESEARCH
- Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor
- (2013) Hideaki Ogiwara et al. CARCINOGENESIS
- 53BP1 Mediates Productive and Mutagenic DNA Repair through Distinct Phosphoprotein Interactions
- (2013) Elsa Callen et al. CELL
- ATR Prohibits Replication Catastrophe by Preventing Global Exhaustion of RPA
- (2013) Luis Ignacio Toledo et al. CELL
- RIF1 Counteracts BRCA1-mediated End Resection during DNA Repair
- (2013) Lin Feng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity
- (2013) Kevin M. Foote et al. JOURNAL OF MEDICINAL CHEMISTRY
- ATM- and ATR-Mediated Phosphorylation of XRCC3 Regulates DNA Double-Strand Break-Induced Checkpoint Activation and Repair
- (2013) Kumar Somyajit et al. MOLECULAR AND CELLULAR BIOLOGY
- RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection
- (2013) J. Ross Chapman et al. MOLECULAR CELL
- A Cell Cycle-Dependent Regulatory Circuit Composed of 53BP1-RIF1 and BRCA1-CtIP Controls DNA Repair Pathway Choice
- (2013) Cristina Escribano-Díaz et al. MOLECULAR CELL
- PRP19 Transforms into a Sensor of RPA-ssDNA after DNA Damage and Drives ATR Activation via a Ubiquitin-Mediated Circuitry
- (2013) Alexandre Maréchal et al. MOLECULAR CELL
- Mechanisms of resistance to therapies targeting BRCA-mutant cancers
- (2013) Christopher J Lord et al. NATURE MEDICINE
- A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
- (2013) Stephen J. Pettitt et al. PLoS One
- Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
- (2013) N. Johnson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- 53BP1 Regulates DSB Repair Using Rif1 to Control 5' End Resection
- (2013) M. Zimmermann et al. SCIENCE
- Rif1 Prevents Resection of DNA Breaks and Promotes Immunoglobulin Class Switching
- (2013) M. Di Virgilio et al. SCIENCE
- Mechanisms of Resistance to PARP Inhibitors—Three and Counting
- (2013) Tito Fojo et al. Cancer Discovery
- The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy
- (2012) Remko Prevo et al. CANCER BIOLOGY & THERAPY
- A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2
- (2012) Katharina Schlacher et al. CANCER CELL
- Abstract 5588: A phase I, open label, dose escalation study of an oral mammalian target of rapamycin inhibitor INK128 administered once daily in patients with advanced malignancies
- (2012) Jeffrey R. Infante et al. CANCER RESEARCH
- Abstract 2814: Potent and selective small molecule inhibitors of polo-like kinase 1: Biological characterization
- (2012) Sheelagh Frame et al. CANCER RESEARCH
- BRCA1 Functions Independently of Homologous Recombination in DNA Interstrand Crosslink Repair
- (2012) Samuel F. Bunting et al. MOLECULAR CELL
- A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response
- (2012) Britt Adamson et al. NATURE CELL BIOLOGY
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
- (2011) A Peasland et al. BRITISH JOURNAL OF CANCER
- Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11
- (2011) Katharina Schlacher et al. CELL
- Analysis of protein dynamics at active, stalled, and collapsed replication forks
- (2011) B. M. Sirbu et al. GENES & DEVELOPMENT
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
- (2011) Philip M Reaper et al. Nature Chemical Biology
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
- (2010) N. Issaeva et al. CANCER RESEARCH
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
- (2010) Samuel F. Bunting et al. CELL
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
- (2010) Peter Bouwman et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- PALB2 Links BRCA1 and BRCA2 in the DNA-Damage Response
- (2009) Feng Zhang et al. CURRENT BIOLOGY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- PALB2 is an integral component of the BRCA complex required for homologous recombination repair
- (2009) S. M. H. Sy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Secondary BRCA1 Mutations in BRCA1-Mutated Ovarian Carcinomas with Platinum Resistance
- (2008) E. M. Swisher et al. CANCER RESEARCH
- A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity
- (2008) Christopher J. Lord et al. DNA REPAIR
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now